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Background: C‑reactive protein (CRP) and white blood cell (WBC) are proinflammatory markers. They are major pathophysiological 
for the development of metabolic syndrome (MetS). This study aimed to address the independent associations between MetS and 
WBC counts and serum CRP levels and evaluation of their magnitude in relation to the MetS, based on the sex in the Iranian adults. 
Materials and Methods: In this cross‑sectional study, subjects who met the MetS criteria, based on the Adult Treatment Panel III 
were selected from the Isfahan Healthy Heart Program database. A questionnaire containing the demographic data, weight, height, 
waist, and hip circumference of the respondents was completed for each person. Blood pressure was measured and the anthropometric 
measurements were done, and fasting blood samples were taken for 2 h postload plasma glucose (2 hpp). Serum [total, high‑density 
lipoprotein (HDL), and low‑density lipoprotein] levels of cholesterol, triglyceride, and CRP as well as WBC counts were determined. 
The univariate analyses were carried out to assess the relation between the CRP levels, WBC counts with the MetS in both sexes the. 
Results: In men with the abdominal obesity, the higher levels of WBC count, high serum triglyceride and blood glucose levels, a low 
serum HDL level, and raised systolic and diastolic blood pressure were observed. However, the higher serum CRP levels were only 
observed in those with the low serum HDL‑cholesterol levels. The mean values of the WBC counts were statistically different between 
the men with and without MetS, but the mean values of the CRP levels were similar between the two groups. In women, the mean 
values of WBC count and CRP levels were statistically different in the subjects with and without a MetS components (except for the 
low serum HDL levels and high diastolic blood pressure for the WBC measures and abdominal obesity for the CRP measures) and for 
those with and without MetS. The age and smoking adjusted changes in the CRP levels and WBC counts correlated with the number 
of Mets components in the women. Conclusion: The findings of this study suggest substantial implications for the prevention and 
management of the MetS and atherosclerotic diseases, as these involve the suppression of inflammatory conditions rather than the 
incitement of anti‑inflammatory conditions.
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of developing diabetes mellitus and cardiovascular 
disease.[4,5]
Inflammation is a major pathophysiological factor for 
the MetS development. Some evidences are available 
concerning the association between the appearance 
of MetS and chronic inflammatory response, 
characterized by the abnormal cytokine production 
and the activations of inflammatory signaling 
pathways.[6,7] Furthermore, some inflammatory 
biomarkers, such as C‑reactive protein (CRP) and 
interleukin‑6 are in associated with the MetS and its 
components in different settings.[6‑13] Moreover, there 
is a proven association between the increased white 
INTRODUCTION
Metabolic syndrome (MetS) is conceptualized as a 
clustering of risk factors, including insulin resistance, 
dyslipidemia, central adiposity, and high blood 
pressure that increase the risk of cardiovascular 
disease and type 2 diabetes mellitus. The combination 
of these findings defines the MetS.[1,2] There is global 
agreement that this risk factors gathering increase the 
risk of cardiovascular disease, and metabolic diseases, 
such as diabetes and thus has made it a serious 
public health problem.[3] In fact, numerous studies 
have shown people with the MetS are more likely to 
die prematurely and that they are at the greater risk 
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blood cell (WBC) count as a biological marker of systemic 
and the components of the MetS.[14,15]
Nevertheless, there are few studies examining sex‑based 
associations between the CRP level and WBC count as 
pro‑inflammatory markers and the MetS, especially in our 
population. Indeed, other published findings achieved 
from small size populations. Therefore, this study aimed 
to investigate the independent associations between the 
MetS and WBC count and serum CRP levels in both sexes 
and evaluation of their magnitude in relation to the MetS 
in the Iranian adults.
MATERIALS AND METHODS
Study population
The Isfahan Healthy Heart Program is a comprehensive 
integrated community‑based action‑oriented study with 
a reference community has been conducted by the Isfahan 
Cardiovascular Research Institute since 2000 and completed 
in 2007 in Isfahan.[16,17] A random independent sample of 
adults was selected by the multistage cluster sampling. The 
effect of confounding was addressed by using the random, 
stratified household sampling, based on age and sex groups. 
The participants were more than 19 years old. Finally, 
4719 subjects with MetS entered in our study. The samples 
underwent a 30‑min interview by well‑trained examiners to 
complete the validated questionnaires containing questions 
on demography, socioeconomic status, smoking behavior, 
physical activity, nutritional habits, and other risk profiles. 
Informed consent was obtained from all subjects prior to 
their participation in this study. This study was approved 
by the Ethical Committee of the Isfahan University of 
Medical Sciences. Isfahan Healthy Heart Program (IHHP) 
was covered under the institutional review board protocol 
FW A00008578.
Data collection
Information on the sociodemographic factors and 
self‑reported medical history were obtained by interview. 
Anthropometric measurements, including height, weight, 
and waist and hip circumferences were taken with the 
subjects wearing light clothing by well‑trained examiners. 
Waist circumference was measured to the nearest 0.1 cm in 
the horizontal plane at the high point of the iliac crest during 
minimal respiration.[17] Blood pressure was measured 
with a mercury sphygmomanometer using right arms, in 
a sitting position, after a 5‑min rest. Systolic and diastolic 
blood pressures were recorded twice and the averages 
were used for the data analysis. Blood samples were 
drawn from anantecubital vein after an 8‑12 h overnight 
fast. Samples were stored at −20°C until required for the 
biochemical assays. Fasting venous blood samples were 
obtained from the antecubital vein between 08:00 and 
09:30 am. Blood samples were centrifuged for 10 min at 
906 g within 30 min of collection. Sera were analyzed for 
the total cholesterol (TC), high‑density lipoprotein (HDL), 
triglycerides (TG), and fasting blood glucose (FBG). 
Low‑density lipoprotein‑cholesterol (LDL) was calculated 
by Friedwald equation when TG was less than 400 mg/dL.[18] 
TC was measured using enzymatic colorimetric methods. 
HDL‑C was determined after dextran sulphate‑magnesium 
chloride precipitation of HDL. The serum CRP levels were 
measured with the same autoanalyzer. The assay (Pars 
Azmoun) had a limit of detection 0.05 mg/L and an upper 
limit of 160 mg/L. WBC count was determined using the 
sysmex.[16,17] All the tests were performed in the Central 
Laboratory of the Isfahan Cardiovascular Research Center 
using the autoanalyzer ELAN (Ependorf 2000). For 
quality‑control measures, this laboratory meets the criteria 
of the national standard laboratory (a WHO collaborating 
centre in Tehran).
MetS definition
The ATPIII definition of MetS was met when three or more of 
the following criteria were present: Waist circumference ≥102 
in cm the men and 88 cm in the women; HDL ≤40 mg/
dL in the men and 50 mg/dL in the women or specific 
treatment for this lipid abnormality; TG ≥150 mg/dL or 
specific treatment for this lipid abnormality; systolic blood 
pressure ≥130 mm Hg or diastolic blood pressure ≥85 
mm Hg or treatment of previously diagnosed hypertension; 
and fasting glucose ≥100 mg/dL.[14]
Statistical analyses
Results were reported as mean ± standard deviation for the 
quantitative variables and percentages for the categorical 
variables. The groups were compared using the t-test for 
the continuous variables and the Chi‑square test for the 
categorical variables. P values of 0.05 or less were considered 
significant. All the statistical analyses were performed 
using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) for 
Windows.
The associations between the serum CRP levels and WBC 
count with the MetS components were examined with the 
logistic regression analysis. The significance level was set 
at P > 0.05.
RESULTS
The personal and clinical characteristics of the study 
subjects are presented in Table 1. Systolic and diastolic 
blood pressures were significantly higher in the men than 
in the women. Serum CRP and blood sugar levels were 
similar between the two genders. Levels of triglyceride and 
WBC counts were higher in the men compared with the 
women. Conversely, LDL cholesterol levels were higher in 
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Table 1: Demographic and clinical characteristics of the study subjects by sex
Characteristics Total (n, %) Men (n, %) Women (n, %) P value
Age
19-24 years 924 (19.6) 459 (19.7) 465 (19.5) 0.987
25-34 years 1439 (30.5) 718 (30.9) 721 (30.2)
35-44 years 923 (19.6) 447 (19.2) 476 (19.9)
45-54 years 650 (13.8) 322 (13.8) 328 (13.7)
55-64 years 356 (7.6) 173 (7.4) 183 (7.7)
≥65 years 420 (8.9) 206 (8.9) 214 (9.0)
Mean age (year) 38.54±15.27 38.48±15.45 38.61±15.10 0.775
Systolic blood pressure (mm Hg) 112.91±18.27 115.75±17.31 110.14±18.76. 0.000
Diastolic blood pressure (mm Hg) 74.43±11.06 76.13±10.50 72.76±11.34 0.000
Fasting blood glucose (mg/dL) 101.25±32.89 100.61±34.53 101.87±31.23 0.209
Triglyceride (mg/dL) 142.66±105.95 154.20±117.82 91.68±1.89 0.000
HDL-cholesterol (mg/dL) 43.46±10.29 40.46±9.11 46.38±10.55 0.000
LDL-cholesterol (mg/dL) 117.90±33.03 115.57±32.47 120.16±33.42 0.000
White blood cell (mg/dL) 6704.55±1640.66 6766.08±1608.57 6642.49±1670.48 0.014
CRP (mg/dL) 2.66±2.23 2.70±2.28 2.62±2.17 0.224
Metabolic syndrome 982 (21.1) 365 (16.0) 617 (26.1) 0.000
Data are presented as mean±standard deviation or number (%); CRP=C‑reactive protein; HDL=High‑density lipoprotein; LDL=Low‑density lipoprotein
Table 2: Metabolic syndrome components and mean value of white blood cell and C‑reactive protein in both sexes
Biomarkers Men Women
Number (%) WBC (103/uL) CRP (mg/L) Number (%) WBC (103/uL) CRP (mg/L) 
Abdominal obesity
Present 292 (12.5) 7259.69±1598.82 2.93±2.45 1183 (49.5) 6856.69±1751.81 2.72±2.45
Absent 1921 (82.6) 6689.95±1608.99 2.68±2.29 1071 (44.8) 6424.79±1567.80 2.56±1.89
P value - 0.000 0.105 - 0.000 0.084
Low HDL-cholesterol
Present 1146 (49.2) 6926.82±1597.30 2.82±2.36 1519 (63.5) 6683.36±1684.34 2.54±2.19
Absent 1139 (48.9) 6612.28±1611.62 2.58±2.19 832 (34.8) 6572.76±1643.22 2.76±2.14
P value - 0.000 0.014 - 0.146 0.027
High triglyceride
Present 851 (36.6) 7108.00±1633.22 2.75±2.10 648 (27.1) 6978.69±1692.65 2.88±2.68
Absent 1431 (61.5) 6554.02±1551.98 2.68±2.39 1711 (71.5) 6516.34±1644.42 2.53±1.95
P value - 0.000 0.501 - 0.000 0.001
High glucose
Present 427 (18.3) 7016.88±1627.66 2.85±2.02 558 (23.3) 6988.33±1932.90 2.71±2.09
Absent 1674 (71.9) 6701.49±1605.03 2.63±2.33 1621 (67.8) 6502.69±1541.60 2.50±1.86
P value - 0.001 0.090 - 0.000 0.033
Systole blood pressure
Present 439 (18.9) 7000.00±1501.47 2.63±1.97 359 (15.0) 6908.78±1916.21 2.97±3.01
Absent 1809 (77.7) 6708.80±1634.34 2.73±2.38 1934 (80.8) 6598.20±1627.98 2.58±2.01
P value - 0.001 0.408 - 0.002 0.004
Diastole blood pressure
Present 386 (16.6) 7030.67±1655.61 2.61±2.09 320 (13.4) 6820.65±1783.43 2.90±3.15
Absent 1861 (80.0) 6711.35±1600.23 2.74±2.35 1970 (82.4) 6618.01±1657.77 2.60±1.99
P value - 0.001 0.329 - 0.062 0.036
Raised blood pressure
Present 606 (26.0) 6983.89±1579.91 2.63±2.03 534 (22.3) 6859.44±1920.59 2.89±2.78
Absent 1641 (70.5) 6685.32±1618.96 2.74±2.39 1756 (73.4) 6581.27±1590.49 2.57±1.98
P value - 0.000 0.321 - 0.002 0.005
Metabolic syndrome
Present 365 (15.7) 7259.04±1512.38 2.87±2.31 617 (25.8) 6963.25±1802.11 2.88±2.73
Absent 1921 (82.6) 6673.78±1612.28 2.67±2.29 1746 (73.0) 6531.13±1607.84 2.53±1.94
P value - 0.000 0.148 - 0.000 0.001
CRP=C‑reactive protein; HDL=High‑density lipoprotein; WBC=White blood cell
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the women. Totally, the overall prevalence of the MetS was 
significantly higher in the women.
Table 2 shows the mean values of CRP levels and WBC 
counts, based on the presence and absence of each 
MetS components and according to the presence and 
absence of MetS in the men. In men, with the abdominal 
obesity a significantly higher level of WBC counts, high 
serum triglyceride and blood glucose levels and, low 
HDL‑cholesterol levels, and raised systolic and diastolic 
blood pressures were observed. However, significantly 
higher serum CRP levels were only observed in those with 
the low HDL‑cholesterol levels. The mean values of WBC 
counts were statistically different between the men with 
and without the MetS, but the mean values of CRP levels 
were similar between the two groups.
In women [Table 3], the mean values of WBC counts 
and CRP levels were statistically different in the subjects 
with and without a MetS component (except for the low 
HDL‑cholesterol levels and high diastolic blood pressure 
for the WBC measures and abdominal obesity for the CRP 
measures) and for those with and without the MetS.
Furthermore, Table 3 hows the association between the CRP 
levels and WBC counts with the presence of the metabolic 
syndrome components. After adjustment for the age and 
smoking, significant relation was found between the 
number of the MetS components and WBC counts in both 
sexes. Association between the CRP levels and the number 
of the MetS components was insignificant.
DISCUSSION
This study aimed to identify the associations between the 
WBC counts and the serum CRP levels with the MetS in 
the adult Iranian population. The results showed that WBC 
counts were associated with the MetS in both men and 
women. However, the CRP levels were only associated with 
the MetS in the women. WBC counts were not significantly 
associated with the low HDL cholesterol levels as well as 
the increased diastolic blood pressure in the men, but this 
association was confirmed between different components 
of the MetS and WBC counts in the men. This result 
supports the findings of previous studies concerning a 
linear independent association between the WBC count and 
the risk of the MetS.[19,20] However, in other studies; finding 
was not specified in men or women. Overall, it seems that 
an increased WBC count may exacerbate insulin resistance 
and lead to the MetS and this pathway might be different 
in the two genders in various populations.
CRP is a sensitive marker of systemic inflammation which 
is produced by the liver.[14] Various studies have reported a 
linear association between the CRP levels and the metabolic 
disorders, including insulin resistance, the MetS, and the 
components of MetS.[21,22] In the Finnish Diabetes Prevention 
Study, CRP introduced as the best immunological predictor 
for the progression from impaired glucose tolerance to overt 
type 2 diabetes.[23] In our study, women participants with 
MetS were found to have significantly higher CRP levels 
than those without. On the contrary, we could not observe 
an independent association between the CRP level and 
MetS in the whole study population. In men, CRP did not 
increase significantly as a risk factor for the development 
of the MetS, while in the women; CRP was in association 
with the MetS. This finding was totally inconsistent with 
the study of Ryu et al.[23] To the best of our own knowledge, 
there is presently no study regarding the association 
between the inflammation and the MetS with sex. In this 
study, some baseline factors differed between the men and 
women, and it is likely that another set of factors related 
to inflammation influence this situation, such as cyclical 
hormonal changes associated with the menstrual cycle 
and subclinical autoimmune reactions.[23] Saltevo et al., 
showed that the levels of proinflammatory markers of 
Table 3: Univariate analyses with between white blood cell and C‑reactive protein with number of metabolic syndrome 
components after adjusting by age and smoking
Sex Number of MetS 
components
WBC CRP
Mean Se P value Mean Se P value
Women 0 6360.317a 185.131 0.000 2.685c 0.247 0.005
 1 6501.961a 176.661 2.370c 0.235
 2 6947.218a 178.819 2.296c 0.238
 3 7112.109a 187.667 2.276c 0.249
 MetS ≥4 7687.177a 207.706 2.785c 0.279
Men 0 6594.448b 67.081 0.000 2.912c 0.096 0.107
 1 6752.981b 64.265 2.659d 0.092
 2 7249.343b 70.918 2.589d 0.103
 3 7515.865b 107.807 2.853d 0.157
 MetS ≥4 7485.372b 154.311 2.857d 0.225
aCovariates appearing in the model are evaluated at the following values: Age (years) = 38.74; bCovariates appearing in the model are evaluated at the following values: Age (years) 
= 38.47; cCovariates appearing in the model are evaluated at the following values: Age (years) = 38.28; dCovariates appearing in the model are evaluated at the following values: 
Age (years) = 38.29; CRP=C‑reactive protein; MetS=Metabolic syndrome; WBC=White blood cell
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CRP and interlukine‑1, were significantly higher among 
the women with the MetS, rather than the men with the 
MetS, independently of the definition used International 
Diabetes Federation and National Cholesterol Education 
Program‑Third Adult Treatment Panel. In contrast, another 
study showed that there was no difference between the 
men and the women without the MetS regarding the 
serum interlukine‑1and CRP levels.[25] In this context, 
a recent meta‑analysis has demonstrated that the high 
testosterone levels are associated with the high risk of 
type 2 diabetes in women, but with low risk in men.[26] 
High concentrations of sex hormone‑binding‑globulin are 
associated with the decreased risk of diabetes, particularly 
in the postmenopausal women.[27] Overall, although 
available data on the effects of gender relationships between 
the serum CRP levels and the MetS or atherosclerosis have 
been reported;[28] further prospective studies are required 
to confirm the contribution of CRP and other inflammatory 
markers to the development of the MetS. If this were 
confirmed, it would have substantial implications for the 
prevention and management of the MetS and atherosclerotic 
diseases, as these involve the suppression of inflammatory 
conditions rather than the incitement of anti‑inflammatory 
conditions.
Limitation
The main limitation of this study was its cross‑sectional 
design. In addition, this study could not show the temporal 
ordering of the association between the CRP levels, WBC 
counts and the MetS. Further longitudinal investigations 
are needed to confirm these associations.
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